Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial.

ABSTRACT:

Background

Vitamin D deficiency has been associated with multiple diseases, but the causal relevance and underlying processes are not fully understood. Elucidating the mechanisms of action of drug treatments in humans is challenging, but application of functional genomic approaches in randomized trials may afford an opportunity to systematically assess molecular responses.

Methods

In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling individuals aged over 65 years were randomly allocated to treatment with vitamin D₃ 4000 IU, 2000 IU or placebo daily for 12 months. Genome-wide genotypes at baseline, and transcriptome and plasma levels of cytokines (IFN-

SUBMITTER: Berlanga-Taylor AJ 

PROVIDER: S-EPMC6013786 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature